Impact of meningococcal group B OMV vaccines, beyond their brief
نویسندگان
چکیده
منابع مشابه
Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV)
The utility of wild-type outer membrane vesicle (wtOMV) vaccines against serogroup B (MenB) meningococcal disease has been explored since the 1970s. Public health interventions in Cuba, Norway and New Zealand have demonstrated that these protein-based vaccines can prevent MenB disease. Data from large clinical studies and retrospective statistical analyses in New Zealand give effectiveness esti...
متن کاملGonococcal Vaccine Development: Lessons from Group B Meningococcal Vaccines
A retrospective case-control study, published online in The Lancet on July 10, 2017, reported that MeNZB–a group B meningococcal vaccine– was effective for preventing gonorrhea acquisition. The vaccine was administered to about 1 million adolescents in New Zealand between 2004 and 2006, and gonorrhea cases fell 31% in those vaccinated compared to unvaccinated controls. The exact mechanisms by w...
متن کاملMeningococcal group C conjugate vaccines
In November 1999 the Department of Health introduced a national vaccination programme using newly licensed meningococcal serogroup C conjugate vaccines (MenC). In the largest national mass vaccination campaign ever undertaken in the UK, all people under the age of 18 years are being oVered vaccination: three doses for infants as part of the primary vaccination schedule at 2, 3, and 4 months of ...
متن کاملMeningococcal group C conjugate vaccines
In November 1999 the Department of Health introduced a national vaccination programme using newly licensed meningococcal serogroup C conjugate vaccines (MenC). In the largest national mass vaccination campaign ever undertaken in the UK, all people under the age of 18 years are being oVered vaccination: three doses for infants as part of the primary vaccination schedule at 2, 3, and 4 months of ...
متن کاملMeningococcal group C conjugate vaccines
In November 1999 the Department of Health introduced a national vaccination programme using newly licensed meningococcal serogroup C conjugate vaccines (MenC). In the largest national mass vaccination campaign ever undertaken in the UK, all people under the age of 18 years are being oVered vaccination: three doses for infants as part of the primary vaccination schedule at 2, 3, and 4 months of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Human Vaccines & Immunotherapeutics
سال: 2017
ISSN: 2164-5515,2164-554X
DOI: 10.1080/21645515.2017.1381810